On April 14, 2026 PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") reported that two research abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2026, taking place April 17–22 in San Diego, California. Both abstracts highlight ongoing development of the Company’s PanGIA Analysis System ("PAS"), a machine learning platform designed to support non-invasive cancer detection through advanced biomarker analysis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reflecting the Company’s continuing research into expanding the capabilities of the PAS across early detection applications, the accepted abstracts include:

"Our mission is to enable earlier detection to help facilitate better patient outcomes, reducing patient mortality. The acceptance of these abstracts is a step in that direction," said Holly Magliochetti, CEO and Co-Founder of PanGIA Biotech. "Opportunities like presenting at AACR (Free AACR Whitepaper) allow us to contribute to the broader conversation shaping the future of cancer diagnostics."

As one of the world’s leading scientific forums for cancer research, the AACR (Free AACR Whitepaper) Annual Meeting brings together clinicians, researchers, and industry leaders to share advances in oncology and translational medicine.

The Company’s research builds on ongoing work to expand the analytical capabilities of the PAS platform and support multi-cancer early detection approaches.

"Presenting this work at AACR (Free AACR Whitepaper) provides an opportunity to share how PanGIA Biotech’s research and development applies machine learning to complex biomolecular signals in non-invasive samples," said Obdulio Piloto, PhD, co-founder and Chief Scientific Officer of PanGIA Biotech and co-author of the studies. "Our research continues to explore how these analytical approaches may support earlier and more scalable cancer detection."

(Press release, PanGIA Biotech, APR 14, 2026, View Source [SID1234664370])